Archive for the ‘Diabetes’ Category

The number of people living with diabetes mellitus in the U.S. has crossed the 20 million mark, with 1.5 million cases having been diagnosed in 2005 alone. Because nearly 65% of this population will suffer from heart disease or stroke, it is crucial for health care professionals to continually investigate the efficacy of current diabetes […]

It is expected that the usual dose of canadian rimonabant will be 20 mg once daily before breakfast. No dosage adjustment is recommended for the elderly, but this agent should be used with caution in patients older than 75 years of age.

Four published clinical trials have assessed the efficacy and safety of rimonabant in the treatment of obesity and cardiometabolic risk factors. Other studies of the drug have been presented as posters at clinical meetings, but they are not reviewed in this article. The iSmonabant In Obesity (RIO) Program consists of four published clinical trials comparing […]

Rimonabant [,/V-piperino-5-(4-chloro-phenyl)-1-1(2,4-dichlorophenyl)-4-meth-ylpyrazole-3-carvoxamide] is a CB1 antagonist. At low concentrations, it may also act as an inverse agonist.8 At very high concentrations, canadian rimonabant also behaves as a CB2 receptor antagonist, blocks calcium and potassium channels, and may directly affect cellular gap junctions. Cannabinoid receptors are members of the G-protein coupled receptor (GPCR) superfamily of cell-surface […]

Rimonabant (Acomplia)

12, Mar 2010

INTRODUCTION The prevalence of obesity continues to rise. Current data indicate that the combined prevalence of overweight and obesity in adults in the U.S. is 66.3%. The prevalence for obesity alone in adults is 32.2%; for extreme obesity in adults, this figure is 4.8%. Approximately 17.1% of children and adolescents in the U.S. are overweight. […]

Our results agree with the previous reports that plasma lipid concentrations are higher among Nigerian hypertensives and diabetics than controls,16-19 and that plasma lipid concentrations are lower in this population than in Caucasians.34’35 Racial variations in plasma lipid concentrations are largely attributable to differ¬ences in the fiber component of diet. Traditional African diet is high […]

The baseline data of patients and controls are shown in Table 1. The controls, normoglycaemic hypertensives, normotensive diabetics and diabetic hypertensives were similar in age, body mass index, and male to female ratio. The duration of diagnosis of hypertension was 6.0 ±3.2 years among the normoglycaemic hypertensives and 5.8 ± 2.2 years among type 2 […]